

# One size does not fit all: Monitoring and management of **ANTI-DRUG ANTIBODIES** in lysosomal diseases with a focus on Fabry disease

Join us on Friday, February 24, from 5:15 – 6:15 pm  
at the Hilton Orlando, Florida Meeting Room

## JOIN US TO HEAR THE PANEL'S PERSPECTIVE

In this symposium, the presenters will discuss mechanisms by which enzyme replacement therapies can trigger the development of anti-drug antibodies (ADAs) in patients with lysosomal storage disorders, with a focus on Fabry disease.

This symposium will also provide insights on the potential predictors of ADA development, effects of ADAs on clinical outcomes, and the real-world management of ADAs. The presenters will then discuss best practices and future considerations for preventing, monitoring, and managing ADAs in patients with Fabry disease. The presentation will include case studies and conclude with a Q&A session.

**Refreshments will be provided.**



**This session is sponsored by Chiesi.  
This is not a continuing education (CE) activity.**

This Satellite Symposium is not part of the official *WORLDSymposium™* program, and *WORLDSymposium* does not approve or endorse any commercial products or services discussed during the Satellite Symposium or offered for sale by the corporate supporter of the Satellite Symposium. This Satellite Symposium is not approved for CME by *WORLDSymposium* or any other entity.

Eligibility: Registration for *WORLDSymposium 2023* and an official name badge are required to attend this satellite symposium.

GRDMA-US-EF-00551

## SPEAKERS



**Dr João Gonçalves**  
Professor of Pharmaceutical Sciences,  
University of Lisbon



**Prof Derralynn Hughes**  
Professor of Experimental Haematology  
Lysosomal Storage Disorders Unit,  
Royal Free London NHS Foundation  
Trust and University College London



**Dr Robert Hopkin**  
Professor of Clinical Pediatrics,  
Cincinnati Children's Hospital  
Medical Center

